Over the past few weeks, three of the largest pharmaceutical manufacturers—Eli Lilly, Janssen, and Merck—have publicly reported the 2017 gross and net price changes for their U.S. product portfolios, along with average discounts. As far as I know, these are the only manufacturers that have publicly reported these data. See the links below.
As you will see, the three companies have provided average discounts from list prices of 42% to 51%. Two of the three companies experienced a year-over-year decrease in average net prices.
Payers and PBMs frequently recommend that manufacturers just lower the cost of their drugs. These data demonstrate that’s exactly what these three companies have done. Of course, the price cuts were provided in the form of rebates and discounts to the drug channel. We still don’t know how, if at all, patients benefited from the declining prices for their drugs.
Read more »
Source: Post feed
